Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: A bone damage biomarker?

Scandinavian Journal of Rheumatology

Volumn 37, Issue 6, 2008, Pages 439-444

  Spelling, P ^a   Bonfa, E ^b   Caparbo, V F ^b   Pereira, R M R ^b  

^a Paediatric Rheumatology Division   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADOLESCENT; ARTICLE; BONE EROSION; BONE INJURY; BONE RADIOGRAPHY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOMODULATION; JUVENILE RHEUMATOID ARTHRITIS; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SWELLING;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; BONE AND BONES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 56249099021     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740802116224     Document Type: Article

References (39)

1. Cassidy JT. Juvenile rheumatoid arthritis. In Cassidy JT, Petty RE, editors. Textbook of pediatric rheumatology. 4th edn, Philadelphia, PA: W.B. Saunders Company, 2001: 133-219.
2. Brewer EJ Jr, Bass J, Baum J, Cassidy JT, Fink C, Jacobs J, et al. Current proposed revision of JRA criteria. JRA Criteria Subcommittee of Diagnostic and Therapeutic Criteria of the American Rheumatism Section of the Arthritis Foundation. Arthritis Rheum 1997;20:195-9.
3. Ronchezel MV, Hilario MO, Goldenberg J, Lederman HM, Faltin K Jr, de Azevedo MF, et al. Temporomandibular joint and mandibular growth alterations in patients with juvenile rheumatoid arthritis. J Rheumatol 1995;22:1956-61.
4. Adib N, Silman A, Thomson W. Outcome following onset of juvenile idiopathic inflammatory arthritis: II. Predictors of outcome in juvenile arthritis. Rheumatology 2005;44:1002-7.
5. Vervoordeldonk MJ, Tak PP. Cytokines in rheumatoid arthritis. Curr Rheumatol Rep 2002;4:208-17.
6. Levalampi T, Honkanen V, Lahdenne P, Nieminen R, Hakala M, Moilanen E. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand J Rheumatol 2007;36:189-93.
7. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in bone cell biology. J Mol Méd 2001;79:243-53.
8. Bezerra MC, Carvalho JF, Prokopowitsch AS, Pereira RM. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res 2005;38:161-70.
9. Lerner UH. New molecules in the tumor necrosis factor ligand and receptor superfamilies with importance for physiological and pathologic bone resorption. Crit Rev Oral Biol Med 2004;15:64-81.
10. Teng YT, Nguyen H, Gao X, Kong YY, Gorczynski M, Singh B, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000;106:59-67.
11. Pereira RM, Corrente JE, Chahade WH, Yoshinari NH. Evaluation by dual X-ray absorptiometry (DXA) of bone mineral density in children with juvenile chronic arthritis. Clin Exp Rheumatol 1998;16:495-501.
12. Reed MH, Wilmot DM. The radiology of juvenile rheumatoid arthritis. A review of the English language literature. J Rheumatol 1991;18(Suppl 31):2-22.
13. Mason T, Reed AM, Nelson AM, Thomas KB, Patton A, Hoffman AD, et al. Frequency of abnormal hand and wrist radiographs at time of diagnosis of polyarticular juvenile rheumatoid arthritis. J Rheumatol 2002;29:2214-18.
14. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
15. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
16. Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, et al. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or antitumor necrosis factor alpha agents. Arthritis Rheum 2006;54:1602-7.
17. Almeida PM, Wickerhauser H. Finding a better socio-economic status classification system for Brazil. J Marketing Res 1988;19:240-50.
18. Tanner JM, O'Keefe B. Age at menarche in Nigerian school girls, with a note on their heights and weights from age 12 to 19. Hum Biol 1962;34:187-96.
19. van Rossum MAJ, Zwinderman AH, Boers M, Dijkmans BAC, van Soesbergen RM, Fiselier TJW, et al. Radiologic features in juvenile idiopathic arthritis. Arthritis Rheum 2003;48:507-15.
20. Steinbrocker O. Prognosis for employability in the major arthritides rheumatoid arthritis, osteoarthritis and gout. Pa Med 1969;72:82-5.
21. Brasil TB, Ferriani VP, Machado CS. Health-related quality of life survey about children and adolescents with juvenile idiopathic arthritis. J Pediatr (Rio J) 2003;79:373; author reply 374.
22. Bezerra MC, Calomeni GD, Caparbo VF, Gebrim ES, Rocha MS, Pereira RM. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Rheumatology 2005;44:1503-6.
23. Santiago RA, Silva CA, Caparbo VF, Sallum AM, Pereira RM. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. Scand J Rheumatol 2008;37:40-7.
24. Theill LE, Boyle WJ, Penninger JM. RANKL and RANK: T cells, bone loss and mammalian evolution. Annu Rev Immunol 2002;20:795-823.
25. Walsh MC, Choi X. Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003;14:251-63.
26. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentation factor. Arthritis Rheum 2000;43:250-8.
27. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, et al. Expression of osteoclast differentation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000;43:821-6.
28. Stern A, Laughlin GA, Bergstrom J, Barret-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 2007;156:555-62.
29. Masi L, Simonini G, Piscitelli E, Del Monte F, Giani T, Cimaz R, et al. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? J Rheumatol 2004;31:986-91.
30. Kerschan-Schindl K, Wendlova J, Kudlacek S, Gleiss A, Woloszczuk W, Pietschmann P. Serum levels of receptor activator of nuclear factor kappa B ligand (RANKL) in healthy women and men. Exp Clin Endocrinol Diabetes. 2007; Dec 10 [Epub ahead of print]; DOI: 10.1055/s-2007-993142.
31. Sarma PK, Misra R, Aggarwal A. Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. Clin Rheumatol 2008;27:289-94.
32. Pereira RM, Delany AM, Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 2001;28:484-90.
33. Canalis E. Mechanism of glucocorticoid action in bone. Curr Osteoporos Rep 2005;3:98-102.
34. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
35. Yilmaz M, Kendirli SG, Altintas D, Bingol G, Antmen B. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol 2001;20:30-5.
36. Kutukculer N, Caglayan S, Aydogdu F. Study of pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin Rheumatol 1998;17:288-92.
37. Huang JL, Kuo ML, Hung IJ, Wu CJ, Ou LH, Cheng JH. Lowered IL-4-producing T cells and decreased IL-4 secretion in peripheral blood from subjects with juvenile rheumatoid arthritis. Chang Gung Med J 2001;24:77-83.
38. Pettit AR, Ji H, von Stechow D, Müller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
39. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90.